Clovis Oncology, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2018-10-30: Form 8-K; Period of report 2018-10-30; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2018-10-29: Form 8-K; Period of report 2018-10-29; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2018-10-12: Form 8-K; Period of report 2018-10-11; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events; Details 5.02.
- 2018-08-01: Form 8-K; Period of report 2018-08-01; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2018-10-30 | 8-K | 2018-10-30 | 2.02 Results of Operations and Financial Condition | 2.02 On October 30, 2018, Clovis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2018. | a51891383.htm |
| 2018-10-29 | 8-K | 2018-10-29 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On October 29, 2018, Clovis Oncology, Inc. (the “Company”) announced that Corwin Dale Hooks, Senior Vice President and Chief Commercial Officer of the Company, has resigned from the Company effective as of October 29, 2018 in order to pursue other opportunities. | d642626d8k.htm |
| 2018-10-12 | 8-K | 2018-10-11 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On October 11, 2018, the Board of Directors (the “Board”) of Clovis Oncology, Inc. (the “Company”) increased the number of members of the Board from nine (9) to eleven (11). 8.01 Following the Company’s 2018 Annual Meeting of Stockholders at which the proposed Non-Employee Director Compensation Policy did not receive the affirmative vote of a majority of the shares of the Company’s common stock entitled to vote at the meeting, the Compensation Committee of the Board undertook another review of the compensation program of the Company’s Non-Employee Directors. | d637888d8k.htm |
| 2018-08-01 | 8-K | 2018-08-01 | 2.02 Results of Operations and Financial Condition | 2.02 On August 1, 2018, Clovis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2018. | a51846824.htm |
| 2018-06-07 | 8-K | 2018-06-07 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The Annual Meeting of Shareholders (the “Annual Meeting”) of Clovis Oncology, Inc. (the “Company”) was held on June 7, 2018. | d602307d8k.htm |
| 2018-05-08 | 8-K | 2018-05-08 | 2.02 Results of Operations and Financial Condition | 2.02 On May 8, 2018, Clovis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2018. | a51803015.htm |
| 2018-04-19 | 8-K | 2018-04-16 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 8.01 Other Events | 1.01 On April 16, 2018, Clovis Oncology, Inc. (the “Company”) entered into an underwriting agreement (the “Common Stock Underwriting Agreement”) with J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, as underwriters (the “Underwriters”), relating to the issuance and sale of 1,837,898 shares of common stock, par value $0.001 per share, of the Company (the “Shares”). 2.03 The information required by this Item 2.03 relating to the Notes and the Indenture is contained in Item 1.01 above and is incorporated herein by reference. 8.01 On April 16, 2018, the Company issued a press release announcing the commencement of the offerings. | d575484d8k.htm |
| 2018-04-10 | 8-K | 2018-04-09 | 8.01 Other Events | 8.01 On April 9, 2018, the staff (the “Staff”) of the Securities and Exchange Commission’s (the “SEC”) Division of Enforcement issued “Wells notices” to Clovis Oncology, Inc. (the “Company”) and certain of its current and former officers stating that the Staff has made a preliminary determination to recommend that the SEC file civil enforcement action(s) against the Company and such officers, alleging violations of certain provisions of the Securities Act of 1933 and the Securities Exchange Act of 1934 relating to the Company’s regulatory update announcement in November 2015 that the FDA requested additional clinical data on the efficacy and safety of rociletinib. | d568152d8k.htm |
| 2018-02-26 | 8-K | 2018-02-26 | 2.02 Results of Operations and Financial Condition | 2.02 On February 26, 2018, Clovis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2017. | a51764664.htm |